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Murine AIDS (MAIDS) develops in susceptible mouse strains after infection with the LP-BM5 murine leukemia virus
complex that contains causative defective, and ecotropic helper, retroviruses. We previously demonstrated that the MAIDS-
resistant H-2d strains BALB/cByJ and C57BL/KsJ generate MHC class I (Kd) restricted virus-specific CD81 cytolytic T
lymphocytes (CTLs) that lyse cells expressing either defective or ecotropic gag proteins. In contrast, the congenic BALB.B
and closely related C57BL/6J MAIDS-susceptible H-2b strains were unable to serve as a source of gag-specific CTLs
(Schwarz and Green, 1994), suggesting that anti-gag CTLs might provide a basis for resistance to MAIDS. Although its
susceptibility to MAIDS was unknown, the (BALB/c 3 C57BL/6J) F1 (CBY6F1) strain could also produce H-2
d-, but not H-2b-,
restricted, anti-gag CTLs (Schwarz and Green, 1994). Because of this correlation between anti-gag CTLs and resistance to
MAIDS, it was important to provide more direct evidence in support of CTL-mediated protection and to determine both the
fine specificity of CByB6F1 anti-gag CTLs, in comparison with the resistant C57BL/Ks and BALB/c strains, and the
susceptibility of this F1 strain to LP-BM5-induced MAIDS. We report here that no symptoms of MAIDS were observed in
CBY6F1 (H-2
d3b) mice. For F2 mice, in contrast to the high susceptibility of H-2
b/b mice, 77% of H-2d/d and 81% of H-2b/d F2 mice
did not exhibit MAIDS after LP-BM5 infection. These results are in contrast to other published studies that concluded that
susceptibility, rather than resistance, is dominant in F1 (resistant 3 susceptible or susceptible 3 resistant) mice. We also
show that CBY6F1 anti-gag CTLs exhibit a fine specificity shared by the MAIDS-resistant BALB/c and C57BL/Ks strains, that
is, the immunodominant gag epitope, SYNTGRFPPL, encoded by an alternative open reading frame. Together with our direct
demonstration here that in vivo monoclonal antibody (mAb) depletion of CD81 T cells converts genetically resistant mice to
MAIDS susceptibility, these data on the ability to mount anti-ORF2/SYNTGRFPPL, gag-specific CTL responses strongly
suggest that CTLs are a primary factor in determining MAIDS resistance. Accordingly, given the Kd-restricted nature of the
CTLs, the main genetic determinant of resistance appeared to be the codominant expression of the resistant H-2d haplotype.
Interestingly, however, 19% of H-2d/b and 23% of the H-2d/d F2 mice had at least one clinical aspect of MAIDS, suggesting that
a non-MHC genetic determinant(s) can negatively influence T-cell protection and thus disease outcome © 2000 Academic PressKey Words: cytolytic T lymphocytes; antigens; peptides; epitopes; antigen presentation; MAIDS; rodent; immunodeficiency
disease; mRNA; MHC.INTRODUCTION
The LP-BM5 isolate of murine retroviruses induces a
profound and progressive immunodeficiency in certain
inbred strains of mice (Mosier et al., 1985; Aziz et al.,
1989; Jolicoeur, 1991; Morse et al., 1992). After infection,
there is an early hypergammaglobulinemia and a gener-
alized enlargement of lymphoid organs, including the
spleen and lymph nodes, probably due to an inappropri-
ate activation and resultant proliferation of both B and T
lymphocytes. Ultimately, T and B lymphocytes are ren-
dered hyporesponsive to either antigenic or mitogenic
challenge. As a consequence, LP-BM5-infected, immu-
nosuppressed mice die after exposure to environmental1 To whom reprint requests should be addressed. Fax: (603) 650-
223. E-mail: William.R.Green@Dartmouth.edu.
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438pathogens that cause only minor infections in healthy
mice (Buller et al., 1987). Because some of these disease
features resemble those of humans infected with HIV,
this mouse model is referred to as murine AIDS (MAIDS).
Although three classes of murine retroviruses have
been isolated from the LP-BM5 mixture, neither the BM5
ecotropic (BM5) nor mink cell cytopathic focus-inducing
(MCF) replication-competent viruses, alone or in combi-
nation, are able to cause MAIDS (Aziz et al., 1989; Chat-
topadhyay et al., 1989). Rather, the BM5 and MCF viruses
serve as helper viruses for the transmission of a repli-
cation-defective virus, which is the proximal etiological
agent of MAIDS (Jolicoeur, 1991; Chattopadhyay et al.,
1989, 1991). Large deletions within the pol and env genes
of this defective virus result in the production of only a
modified gag protein (Huang and Jolicoeur, 1990). With
the exception of a continuous stretch of about 25 amino
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439ANTI-GAG CTLs SPECIFIC FOR AN ALTERNATIVE ORFacids (AA) in the COOH-terminus of p15 and 25 AA in the
N-terminus of p12, the gag polyprotein encoded by the
defective virus shares significant homology with other
murine retroviruses, including the BM5 ecotropic helper
virus.
We have previously demonstrated that MAIDS-resis-
tant, BALB/cByJ (BALB/c) and C57BL/KsJ (C57BL/Ks)
(H-2d) mice generate MHC class I-restricted gag-specific
D81 cytolytic T lymphocytes (CTLs), which lyse cells
xpressing either defective (dG) or ecotropic (eG) gag
roteins, as encoded by recombinant Sindbis virus or
accinia (Vac) virus expression. In contrast to these
AIDS-resistant strains, the congenic BALB.B (H-2b) and
closely related C57BL/6J (H-2b) MAIDS-susceptible
trains were unable to serve as a source of gag-specific
TLs (Schwarz and Green, 1994), suggesting that anti-
ag CTLs might play a key role in resistance to LP-BM5-
nduced MAIDS. Furthermore, the (BALB/c 3 C57BL/6J)
1 hybrid (CBY6F1) strain could also be stimulated to
produce a population of H-2d-, but not H-2b-, restricted,
anti-gag CTLs (Schwarz and Green, 1994). Using human
143B or murine MC57 (H-2b) cells coinfected with dG- or
eG-Vac-expressing viruses and recombinant vaccinia vi-
ruses expressing different H-2d class I molecules, it was
hown that the anti-gag CTLs recognized a viral
pitope(s) presented in the context of H-2Kd (Schwarz
and Green, 1994). In addition, we subsequently demon-
strated that the fine specificity of BALB/c-derived, anti-
gag CTLs was accounted for by a uniquely produced
epitope encoded in an alternative translational open
reading frame (ORF). Relative to the primary ORF (ORF1)
that encodes the structural defective or ecotropic viral
gag protein, the CTLs were specific for a minimal peptide
determinant defined as the ORF2-generated SYNTGRF-
PPL epitope (Mayrand et al., 1998; Mayrand and Green,
1998).
The ability of the CBY6F1 mice to generate gag-spe-
ific CTLs was of particular interest because previous
tudies with several F1 (MAIDS-resistant 3 MAIDS-sus-
ceptible or MAIDS-susceptible 3 MAIDS-resistant)
strains have led to the conclusion that susceptibility,
rather than resistance, is dominant (Makino et al., 1990;
Huang et al., 1992). By way of contrast, Hammelin-
ourassa et al. (1989) demonstrated that F1 progeny of
he susceptible, C57BL/6 3 resistant, A/J strains were
ore resistant than susceptible to LP-BM5 virus-induced
AIDS, and Makino et al. (1991) reported that 55% of the
1 progeny of resistant, RIIIS 3 susceptible, B10.RIII
trains were MAIDS resistant. Taken together, these lat-
er two studies suggest that in certain F1 strains, MAIDS
resistance may be dominant over MAIDS susceptibility,
whereas the opposite may be true for other F1 strains.
Because the CBY6F1 mouse strain can generate gag-
pecific CD81 CTL responses apparently similar to those
haracterized in the MAIDS-resistant BALB/c and
57BL/Ks strains and unlike the MAIDS-susceptible L57BL/6 and BALB.B strains, it was important to deter-
ine the susceptibility of this F1 strain to LP-BM5-in-
uced MAIDS. If anti-gag CTLs are critical for resistance,
t would be paradoxical if CBY6F1 mice would possess a
AIDS-susceptible phenotype, as suggested for the ma-
ority of the (resistant 3 susceptible) F1 strains cited
above. If, indeed, CBY6 F1 mice demonstrate suscepti-
ility to LP-BM5-induced MAIDS, however, differences in
he fine specificity of the gag-specific CTLs generated in
he BALB/c and C57BL/Ks versus CBY6F1 strains could
account for the resistance versus susceptibility among
these mouse strains. Alternatively, perhaps anti-gag
CTLs are not the prime factor in determining resistance.
To further investigate these issues, experiments were
conducted in the present study to address three issues:
(1) Is there direct evidence that CD81 CTLs confer resis-
tance to MAIDS? (2) Do gag-specific CTLs derived from
H-2d mouse strains other than BALB/c (i.e., C57BL/Ks
nd CBY6F1) share the ORF2-derived, SYNTGRFPPL
specificity of the BALB/c-derived anti-gag CTLs? (3) Are
CBY6F1 mice, like many other (resistant 3 susceptible)
F1 strains, susceptible to LP-BM5-induced MAIDS?
RESULTS
n vivo depletion of CD81 CTLs converts resistant
mice to susceptibility to LP-BM5 murine leukemia
virus-induced MAIDS
To directly assess the contribution of CD81 CTLs to
AIDS resistance, prototypical resistant adult BALB/
ByJ mice were depleted in vivo of CD81 T cells, and a
ortion of these were concurrently infected with LP-BM5
irus (as detailed in Materials and Methods). Postinfec-
ion, weekly injections of purified anti-CD8 ascites were
dministered to ensure that CD8 depletion was main-
ained. Confirmation of chronic CD81 T-cell depletion
throughout the experiment was achieved via weekly flow
cytometric analyses of splenocytes from a control group
of mice that received only anti-CD8 treatment: .95%
CD81 cells were eliminated, compared with naive age/
ender-matched untreated mice (data not shown). This
ntreated mouse group was also subdivided into unin-
ected versus LP-BM5-infected control subsets. Six
eeks after LP-BM5 infection, the mice were sacrificed
nd evaluated for several parameters indicative of
AIDS: spleen hyperplasia, elevated serum IgG2a and
gM levels, and diminished mitogenic responses [ConA
nd lipopolysaccharide (LPS)]. LP-BM5-infected C57BL/6
ice, included in parallel as positive controls for the
bility of the LP-BM5 virus preparation used in this ex-
eriment to induce MAIDS, demonstrated characteristi-
ally severe splenic hyperplasia, hypergammaglobuline-
ia, and inhibited mitogenic responses as a measure of
mmunosuppression (data not shown).
As depicted in Fig. 1, anti-CD8 treatment converted
P-BM5-infected BALB/cByJ-resistant mice to clear
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440 MAYRAND ET AL.MAIDS susceptibility, based on these multiple disease
criteria. For example, splenic hyperplasia was obvious.
CD8-depleted and LP-BM5-infected mice exhibited an
average spleen weight of 1.53 6 0.12 g/100 g body weight
(BW) compared with naive mice or mice treated with
either only anti-CD8 (0.50 6 0.09 g/100 g BW; P 5 0.001)
or only LP-BM5 virus (0.55 6 0.04 g/100 g BW; P 5 0.001).
These results were corroborated by both serum IgG2a
and IgM levels (data not shown). Specifically, anti-CD8-
treated/LP-BM5-infected mice were hypergammaglobu-
linemic with average serum IgG2a levels of 558 mg/ml
ompared with either noninfected, anti-CD8-treated mice
209 mg/ml; P 5 0.006) or nondepleted, LP-BM5-infected
mice (245 mg/ml; P 5 0.013). Additionally, anti-CD8-treat-
ed/LP-BM5-infected mice had average serum IgM levels
of 511 6 26 mg/ml compared with noninfected, anti-CD8-
reated mice (146 6 27 mg/ml; P 5 0.001) or nondepleted,
LP-BM5-infected mice (171 6 9.3 mg/ml; P 5 0.001).
Similarly indicative of MAIDS were the immunodefi-
ciency parameters examined. Thus the ability of anti-
CD8-treated/LP-BM5-infected mice to generate T-cell
and B-cell mitogen responses was substantially dimin-
ished compared with both uninfected anti-CD8-treated
mice (P 5 0.001 for ConA and P 5 0.003 for LPS) and
ondepleted, LP-BM5-infected mice (P 5 0.003 for ConA
nd P 5 0.02 for LPS). Collectively, these data demon-
strate that CD81 T cells are required for resistance to
LP-BM5 virus-induced MAIDS, consistent with a direct
FIG. 1. Resistance to LP-BM5 virus-induced MAIDS requires CD81 T
chronically depleted of CD81 T cells by in vivo mAb infusion, or both v
weeks postinfection, the mice were sacrificed, and spleen weight wa
values of ,0.05 were accepted as statistically significant differencerole for BALB/cByJ-derived, gag-/SYNTGRFPPL-specific
CTLs in the resistant phenotype.Identification of the peptide epitope recognized by
gag-specific CTLs derived from the CBY6F1 and
C57BL/Ks mouse strains
To test the possibility that the CBY6F1 strain recog-
ized the same gag-associated CTL specificity as the
AIDS-resistant BALB/c strain, a series of experiments
ere carried out using, as a source of antigen, defective
r ecotropic gag-expressing Sindbis and vaccinia virus
ecombinants and the synthetic, ORF2-derived peptide
hat represents the minimal immunodominant epitope
dentified in BALB/c mice. As shown in the representa-
ive experiment of Table 1, CBY6F1 mice primed and
estimulated with dG-Vac, expressing AA 1–532 of the
efective gag protein (def-gag), efficiently lysed P815B
arget cells either infected with a Sindbis virus express-
ng either def-gag AA 208–240 or AA 1–342, or pulsed
ith the ORF2-derived SYNTGRFPPL peptide (61%, 60%,
nd 58% specific lysis at an effector-to-target (E/T) ratio
f 100:1, respectively) compared with target cells infected
ith a recombinant Sindbis virus expressing def-gag AA
08–225 or noninfected/untreated P815B (mock) target
ells (10% or 21% specific lysis, respectively). Because
f the uniform activity against targets capable of ex-
ressing the ORF2-defined CTL epitope, including syn-
hetic peptide pulsed P815B target cells, but not target
ells infected with SIN:dG(208–225), which does not en-
ode the ORF2 epitope, these results were consistent
ith SYNTGRFPPL as the major specificity of the F1
BALB/c adult mice were either untreated, infected with LP-BM5 virus,
fected and depleted of CD81 T cells (see Materials and Methods). At
mined as an index of MAIDS susceptibility. Student’s t test-determined
g treatment groups.cells.
irus inanti-gag CTL. Similar to dG-Vac in vitro restimulation,
spleen cells from these same dG-Vac primed but not
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441ANTI-GAG CTLs SPECIFIC FOR AN ALTERNATIVE ORFnonimmunized CBY6F1 mice (data not shown) were suc-
cessfully restimulated with recombinant Sindbis viruses
expressing def-gag AA 208–240 or 1–342 but not 208–
225. These CTLs caused substantial lysis above back-
ground of the same set of ORF2 epitope-encoding re-
combinant Sindbis virus-infected P815B target cells and
those target cells pulsed with SYNTGRFPPL peptide (Ta-
ble 1). Reverse transcription–polymerase chain reaction
(RT–PCR) demonstrated that all minigene RNA products
were expressed in the Sindbis-infected target cells used
in this experiment, and maintenance of an ORF was
confirmed by sequencing of the viral plasmids (data not
shown). Collectively, these results regarding anti-gag
CTL fine specificity confirmed in two additional experi-
ments using dG-Vac in vivo priming were consistent with
the hypothesis that the SYNTGRFPPL peptide acts as the
immunodominant CTL epitope in F1 mice.
A CBY6F1 CTL specificity for SYNTGRFPPL was further
upported by experiments demonstrating that CTLs were
lso generated from mice primed with eG-Vac, but not
aive mice, after restimulation of primed spleen cells in
itro with ORF2-derived SYNTGRFPPL peptide. These
TLs efficiently lysed P815B target cells either infected
ith SIN:dG(208–240) or pulsed with the SYNTGRFPPL
eptide compared with little or no lysis of mock infected
arget cells or those infected with SIN:dG(208–225) (Fig.
). RT–PCR was again used to verify expression of all
T
CBY6F1 Mice Generate Anti-Gag CTLs with Sp
Effector cell stimulation
E/T
ratio
Primary
in vivo
Secondary
in vitro Mock SIN:dG
dG-Vac dG-Vacc 100:1 21
20:1 23
Kd-Vacc 100:1 21
20:1 23
None 100:1 0
SIN:dG(208–225)
J774.2 cells 100:1 1
SIN:dG(208–240)
J774.2 cells 100:1 1
20:1 21
SIN:dG(1–342)
J774.2 cells 100:1 21
20:1 22
a 51Cr release assay of CTLs, generated by priming CBY6F1 mice i.p
pleen cells with J774.A2 tumor cells infected with various recombina
nfected or pulsed with 100 pg/ml synthetic (ORF2) peptide epitope. S
b SIN:dG(208–240) and SIN:dG(1–342), versus SIN:dG(208–225) are S
versus do not encode for the ORF2-derived SYNTGRFPPL epitope.
c dG-Vac is a recombinant vaccinia virus construct encoding for the
d MHC class I protein.
d ND, not determined.ecombinant Sindbis-encoded minigene RNA products in
hese P815B target cells (data not shown). The lack of
t
mysis of NK-susceptible Yac-1 target cells underscored
he specificity of the response. Two repeat experiments
mploying eG-Vac priming demonstrated similar results
s those depicted in Fig. 2, suggesting that like the
ALB/c strain, the CBY6F1 mice recognized the ORF2-
erived SYNTGRFPPL epitope of either def- or eco-gag
rigin.
To evaluate the in vivo immunogenicity of ORF2-de-
ived SYNTGRFPPL epitope under conditions where its
xpression was not driven by a recombinant virus ex-
ression system (i.e., Sindbis or vaccinia virus), CBY6F1
mice were primed by infection with the LP-BM5 retroviral
complex and evaluated for their ability to generate sec-
ondary anti-gag, and specifically anti-SYNTGRFPPL, CTL
responses. LP-BM5 primed spleen cells restimulated
with the SYNTGRFPPL peptide efficiently lysed target
cells infected with either SIN:dG(208–240) or SIN:dG(1–
342) (69% or 82% specific lysis, respectively) compared
with mock or SIN:dG(208–225)-infected targets (24% or
20% specific lysis, respectively) at a 100:1 E/T ratio (Table
2). These data provided additional evidence that SYNT-
GRFPPL is the immunodominant peptide recognized by
CBY6F1-derived gag-specific CTL. RT–PCR was again
sed to verify expression of all minigene messages in
he Sindbis-infected P815B target cells, and maintenance
f the insert ORFs was confirmed by sequencing the viral
onstruct (data not shown). These results demonstrated
for the ORF2-Derived SYNTGRFPPL Epitopea
Target cell % specific lysis for P815B cells
5)b SIN:dG(208–240)b SIN:dG(1–342)b
ORF2
SYNTGRFPPL
61 60 58
34 31 38
19 17 NDd
7 8 ND
5 4 4
19 17 19
69 63 67
34 34 26
32 32 42
10 11 15
G-Vac virus (2 3 107 pfu) followed by in vitro restimulation of primed
bis or vaccinia viruses, as indicated. P815 target cells were similarly
ous release values for target cells were 16% or lower.
virus constructs encoding regions of the defective gag protein that do
efective gag protein, whereas Kd-Vac is a control that encodes for theABLE 1
ecificity
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442 MAYRAND ET AL.leads to the physiological production of immunogenic
levels of the SYNTGRFPPL peptide sufficient to prime
SYNTGRFPPL-specific precursor CTLs in CBY6F1 mice,
s we had previously shown in MAIDS-resistant BALB/c
ice (Mayrand et al., 1998). Similar results were ob-
ained in two repeat experiments. Collectively, these data
onfirmed that gag-specific CTLs derived from CBY6F1
mice recognize the same ORF2-derived SYNTGRFPPL
peptide as the MAIDS-resistant BALB/c strain.
Because, as mentioned earlier, a population of gag-
specific CTLs derived from the MAIDS-resistant
C57BL/Ks mouse strain also recognizes a Kd-presented
epitope located within the gag protein of the defective
virus, a similar series of experiments were performed to
determine the CTL fine specificity of this strain. Similar to
BALB/c (Mayrand et al., 1998) and CBY6F1 (Table 2) mice,
FIG. 2. Recognition of the ORF2-derived SYNTGRFPPL by gag-speci
by eG-Vac priming CBY6F1 mice, followed by in vitro restimulation with
sing 51Cr-radiolabeled target cells: P815B, either infected with the ind
100 pg/ml ORF2-derived SYNTGRFPPL peptide, or Yac-1, as a target ce
of 100:1 is shown, although other E/T ratios were used with a similar pat
T
CBY6F1 Mice Primed with LP-BM5 Virus Generate Anti-Gag
Effector cell stimulation
E/T
ratioPrimary in vivo Secondary in vitro Mock
LP-BM5 virus None 100:1 30
20:1 18
ORF2-SYNTGRFPPL 100:1 24
20:1 16
a CTLs were generated by priming CBY6F1 mice i.p. with LP-BM5 viru
0 mg/ml synthetic ORF2 peptide epitope as indicated. Spontaneous rel
ecombinant Sindbis viruses, as described in Table 1, were 11% or lower.
b Yac-1 is a target cell highly susceptible to lysis by NK cells.P-BM5 primed and SYNTGRFPPL peptide or SIN:
G(208–240) restimulated C57BL/Ks effector cells dem-
nstrated substantial lysis (above background levels) of
nly those P815B target cells infected with recombinant
indbis viruses expressing the ORF2-SYNTGRFPPL
pitope, not mock or SIN:dG(208–225)-infected target
ells or NK-susceptible Yac-1 targets (data not shown).
hese findings were supported by data from both a
epeat LP-BM5 priming experiment in which a similar
attern of results was obtained, although the lysis values
ere somewhat lower, and three experiments in which
nti-ORF2/SYNTGRFPPL C57BL/Ks CTLs were produced
fter appropriate in vitro restimulation of dG-Vac primed
ice. Taken together, these results strongly suggested
hat the gag-specific CTLs derived from MAIDS-resistant
57BL/Ks mice recognize the same ORF2-generated
s generated in the CBY6F1 strain. Gag-specific CTLs were generated
tic, ORF2-derived SYNTGRFPPL peptide. Lytic activity was measured
ef-gag-expressing Sindbis recombinants (see Table 1) or pulsed with
y susceptible to lysis by NK cells. Percent specific lysis at an E/T ratio
results. Spontaneous release values for target cells were 28% or lower.
ith Specificity for the ORF2-Derived SYNTGRFPPL Epitopea
arget cell % specific lysis for P815B cells
Yac-1bdG(208–225) SIN:dG(208–240) SIN:dG(1–342)
14 31 32 9
12 21 30 3
20 69 82 7
11 51 61 4
105 pfu, followed by in vitro restimulation of primed spleen cells with
alues for 51Cr-labeled target cells, including those infected with variousfic CTL
synthe
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and CBY6F1 strains.
haracterization of the MAIDS phenotype of the
BY6F1 mouse strain
As discussed, according to the published literature
(Makino et al., 1990; Huang et al., 1992), susceptibility to
AIDS, rather than resistance, is dominant, at least in
he F1 strains used in those studies. Although the CBY6F1
strain might thus be expected to also be susceptible to
LP-BM5-induced MAIDS, it seemed curious to us that
only two of the three H-2d-positive mice strains that were
shown to be capable of generating gag-specific/anti-
SYNTGRFPPL responses would be resistant to MAIDS.
To directly address the issue of MAIDS resistance ver-
sus susceptibility, the disease phenotype of the CBY6F1
strain was assessed via intraperitoneal delivery of LP-
BM5 virus to adult mice, followed by standard measure-
ments of the hallmark MAIDS features: splenomegaly
and hypergammaglobulinemia. As depicted in Fig. 3,
when uninfected versus LP-BM5 virus-infected CBY6F1
mice were compared, no significant differences were
observed (P 5 0.27) with respect to spleen weight at 15
weeks postinfection. By contrast and as expected, sus-
ceptible C57BL/6 mice infected with LP-BM5 had signif-
icant splenomegaly compared with noninfected C57BL/6
mice (P 5 0.005). Additionally, visual observation of the
lymph node sizes indicated no LP-BM5-induced enlarge-
ment in the CBY6F1 mice, whereas massive enlargement
FIG. 3. Determination of the MAIDS phenotype of CBY6F1 mouse via s
i.p. with LP-BM5 virus (1.8 3 105 pfu). At 15 weeks post-virus delivery,
esistance. All mice (n 5 30) were age matched at the time of LP-B
test-determined P values ,0.05 were accepted as statistically significof lymph nodes was observed in infected C57BL/6 mice.
These data suggested that there was no LP-BM5 virus-
uinduced hyperplasia of lymphoid organs in CBY6F1 mice
at a time when B6 mice were found to be MAIDS sus-
ceptible.
As an independent measurement of MAIDS induction,
serum Ig levels were determined at 6 and 15 weeks after
LP-BM5 delivery. As reported in the literature, the serum
Ig levels in highly susceptible C57BL/6 mice achieved
maximal plateau levels at 4–8 weeks after LP-BM5 infec-
tion (Pattengale et al., 1982). Hence, the 6-week serum
samples are shown to demonstrate that although the
LP-BM5-infected C57BL/6 mice had serum IgG2a and
IgM levels significantly higher (P 5 0.01 and 0.001, re-
pectively) than noninfected C57BL/6 mice, no signifi-
ant differences were detected between LP-BM5-in-
ected and naive CBY6F1 mice (IgG2a, P 5 0.28; IgM, P 5
.47; Figs. 4A and 4B, respectively). With disease pro-
ression, the serum Ig levels in MAIDS mice began to
ecline, most likely as a result of the functional inactiva-
ion of the B cells as immunodeficiency develops. As a
esult, the elevation in serum Ig levels from the 15-week
ostvirus serum samples was less pronounced in the
P-BM5-infected C57BL/6 mice but still highly significant
IgG2a, P 5 0.01; IgM, P 5 0.003; data not shown). In
contrast, because as late as 15 weeks after LP-BM5 virus
infection, CBY6F1 mice had serum IgG2a (P 5 0.30) and
gM (P 5 0.42) levels comparable to naive mice, we
oncluded that LP-BM5 infection of adult CBY6F1 mice
oes not cause hypergammaglobulinemia.
Results from an additional independent experiment
yperplasia. Adult (5 weeks old) CBY6F1 or C57BL/6 mice were infected
weight was determined as a measurement of MAIDS susceptibility or
livery. Data depicted represents the group mean 6 SD. Student’s t
erences among treatment groups.pleen h
spleensing the same F1 strain (n 5 15) confirmed the lack of
elevation of serum Ig levels in CBY6F1 mice infected with
i
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444 MAYRAND ET AL.the LP-BM5 virus (data not shown). Because measure-
ments of spleen hyperplasia and hypergammaglobuline-
mia are routinely used as prototypical disease features
to determine MAIDS susceptibility or resistance (Patten-
gale et al., 1982), these data demonstrating both a lack of
splenomegaly and normal serum Ig levels as late as 15
weeks postvirus suggested that contrary to other F1
strains that have been reported on (Makino et al., 1990,
1991; Huang et al., 1992), resistance is dominant over
susceptibility in CBY6F1 mice.
FIG. 4. Determination of the MAIDS phenotype of CBY6F1 mouse via s
mice were infected i.p. with LP-BM5 virus (1.8 3 105 pfu). At 6 weeks p
elative levels of serum IgG2a (A) and IgM (B). All mice (n 5 30) were ag
mean 6 SD. Student’s t test-determined P values ,0.05 were accepteThese results, which are considered in light of our
correlation between MAIDS resistance and the ability to
e
fmount anti-ORF2/SYNTGRFPPL, gag-specific CTL re-
sponses in the context of H-2d, but not H-2b, further
mplied that the primary genetic factor in determining
AIDS resistance versus susceptibility might be the
odominant expression of the resistant H-2d haplotype.
To extend the analysis of the induction of MAIDS in mice
expressing the H-2b and/or H-2d haplotypes, particularly
given the disparity of the findings for F1 strains in the
literature versus our demonstration of the MAIDS-resis-
tant phenotype of CBY6F1 mice (Figs. 3 and 4), additional
g levels after LP-BM5 infection. Adult (5 weeks old) CBY6F1 or C57BL/6
us delivery, mice were bled and an ELISA was used to determine the
hed at the time of LP-BM5 delivery. Data depicted represent the group
tatistically significant differences among treatment groups.erum I
ost-virxperiments were conducted using F2 mice obtained
rom the intercrossing of CBY6F1 mice. The resulting F2
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445ANTI-GAG CTLs SPECIFIC FOR AN ALTERNATIVE ORFmice should allow independent segregation of non H-2
genetic traits possibly influencing the development of
MAIDS from the proposed “resistant” (H-2d/d and H-2b/d)
nd “susceptible” (H-2b/b) H-2 genotypes. When H-2d/d or
H-2b/d mice were compared with H-2b/b F2 mice with
respect to serum Ig levels at various time points after
infection with the LP-BM5 virus, both H-2d/d and H-2b/d F2
mice demonstrated roughly comparable serum Ig levels,
substantially lower than those of the H-2b/b F2 mice,
hich had strongly elevated levels during the 3- to 12-
eek postinfection period (data not shown). This lack of
bvious hypergammaglobulinemia was observed for
oth H-2d/d and H-2b/d F2 mice and was essentially inde-
endent of whether the mice were scored as LP-BM5
efective virus positive or negative by PCR assessment
f viral DNA. The defective virus-positive F2 mice of the
H-2d/d genotype, which is associated with MAIDS resis-
ance (Makino et al., 1990), had somewhat higher levels
f Ig at the 10- to 16-week time period than the defective
irus-positive F2 H-2
b/d mice. However, this elevation in Ig
evels in defective virus-positive H-2d/d mice was tran-
ient, in that it was not sustained at time points extend-
ng out to 24 weeks postinfection. By contrast, all H-2b/b
F2 mice were defective virus positive and presented with
yper-Ig (data not shown), similar to that previously dem-
nstrated for the LP-BM5 infected, prototypic MAIDS-
usceptible B6 mice.
FIG. 5. The absence of splenomegaly and hyper-Ig levels after LP-BM
from MAIDS was conferred by H-2d. CBY6F1 (H-2
d3b) were crossed to
genotyped and then infected with 0.5 ml of LP-BM5 mixture at 6 weeks
were determined by ELISA. At the time of sacrifice (when mice were m
gag by PCR. Spleen size and/or spleen cells counts were determined, a
Data are plotted as the spleen size versus highest Ig level at any poin
Defective gag-negative mice. F, Defective gag-positive mice. H-2b/b m
ound to be virus positive (15 mice) and negative (33 mice), and H-2b/d
Values directly above data points refer to the numbers of mice in each g
H-2d/d mice and H-2b/d mice; the Ig values for virus-negative H-2b/d micFurther analysis of these same LP-BM5 virus-injected
2 mice is depicted in Fig. 5. F2 mice are grouped on the sbasis of their highest serum Ig levels, MHC genotype,
spleen weights, and defective virus status. When all mice
were analyzed in this manner, several distinct differ-
ences emerged. First, with respect to serum Ig levels
after infection with the LP-BM5 virus, most H-2d/d (77%)
nd H-2b/d F2 (81%) mice demonstrated “normal” serum Ig
levels relative to the significantly elevated serum Ig lev-
els of H-2b/b F2 mice. Specifically, 91% of H-2
b/b F2 mice
ad serum Ig levels greater than 5953 mg/ml, which is
he highest value of defective virus-negative H-2b/d mice
(Fig. 5). Second, although only 23% of H-2d/d and 19% of
H-2b/d F2 mice demonstrated at least one aspect of dis-
ase (spleen hyperplasia and/or elevated Ig levels),
00% of H-2b/b F2 mice displayed at least one aspect of
isease (Fig. 5). Third, these results demonstrate that the
evelopment of MAIDS in the “resistant” H-2d/d F2 mice
was similar to that in H-2b/d F2 mice. Thus we found that
H-2b/d mice, whether they be F1 or F2 intercrosses, pre-
sented with a MAIDS-resistant phenotype.
DISCUSSION
Our finding that CBY6F1 (H-2
d3b) and both H-2d/d and
H-2b/d F2 mice possess a MAIDS-resistant phenotype,
compared with H-2b/b F2 mice, was of particular interest
in view of the studies by Makino et al. (1990) and Huang
et al. (1992), which both concluded that susceptibility,
ion correlates with the presence of the H-2d allele, indicating protection
ate H-2b/b, H-2d/d, and H-2d/b intercross progeny. These F2 mice were
. Mice were serially bled at 3- to 4-week intervals, and total Ig levels
d or at 27 weeks), all mice were tested for the presence of defective
merical score of 1, 2, or 3 was assigned (see Materials and Methods).
g the study, and the mean values are indicated for all data groups. E,
e all positive for defective virus (47 mice), whereas H-2d/d mice were
ere found to be both virus positive (32 mice) and negative (52 mice).
or reference, bars are present at the highest Ig levels for virus-negative
sed as the uninfected Ig value for H-2b/b mice.5 inject
gener
of age
oribun
nd a nu
t durin
ice wer
mice wrather than resistance, is dominant in F1 (resistant 3
usceptible or susceptible 3 resistant) mice. Makino et
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446 MAYRAND ET AL.al. (1990) used F1 hybrids of the MAIDS-susceptible,
C57BL/6 or C57BL/10) strain crossed with a highly re-
istant (B10.D2 or A/J) or moderately resistant (B10.BR or
10.A) strain in the evaluation of the dominance of sus-
eptibility versus resistance to LP-BM5 virus-induced
AIDS. Although limited by the number of animals eval-
ated, this study concluded that all F1 strains examined
demonstrated some signs of MAIDS (i.e., splenomegaly
and histopathology) by 10 weeks postinfection. Interest-
ingly, most F1 strains examined by Makino et al. (1990)
demonstrated a significantly delayed onset of disease.
Although disease onset occurred at 3–4 weeks in proto-
typic, MAIDS-susceptible C57BL/6 mice, MAIDS onset
was not clearly identified until 10–15 weeks postinfection
in the F1 mice (Makino et al., 1990). In keeping with the
otion of F1 MAIDS susceptibility but with kinetics similar
o those of B6 mice, Huang et al. (1992) demonstrated
AIDS onset as early as 4–5 weeks in F1 progeny of
usceptible C57BL/6N females crossed with males from
he resistant LG/J strain. Taken together, the data from
hese two studies suggested that although disease on-
et may be delayed in some F1 strains, MAIDS suscep-
ibility appears to be dominant over resistance.
In direct contrast to these findings, we report here that
o symptoms of MAIDS onset were observed in CBY6F1
(H-2d3b) mice, whereas 77% of H-2d/d and 81% of H-2b/d F2
mice did not exhibit MAIDS after LP-BM5 infection.
These data are consistent with a study by Hammelin-
Bourassa et al. (1989) that demonstrated F1 progeny of
he susceptible C57BL/6 3 resistant A/J strains were
ore resistant than susceptible to LP-BM5 virus-induced
AIDS. Additionally, Makino et al. (1991) reported that
nly 45% of the F1 progeny of the resistant RIIIS 3
susceptible B10.RIII strains were MAIDS susceptible.
Given the apparent strain dependence of the dominance
of resistance or susceptibility to MAIDS of F1 mice and
the disparate findings reported by various laboratories, a
more complete analysis of the inheritance of genes con-
trolling MAIDS resistance versus susceptibility in F1 and
F2 mice may help to explain the reported differences.
ndeed, Makino et al. (1990) demonstrated that non-MHC
ackground genes influenced the development of
AIDS. We also find a small subset of resistant H-2d/d F2
mice somewhat susceptible to MAIDS, consistent with
the interpretation that non-H-2 genes influenced the de-
elopment of MAIDS.
Our finding that CBY6 F1 mice generate anti-gag-spe-
cific CTLs with a fine specificity shared by the MAIDS-
resistant BALB/c and C57BL/Ks strains (Table 1, Fig. 2)
supports the argument that (resistant 3 susceptible) F1
mice that are capable of responding to defective gag are
resistant to LP-BM5-induced MAIDS. The results de-
scribed in this report should also be considered in light
of our previous correlation between MAIDS resistance
and the ability to mount such anti-ORF2/SYNTGRFPPL,
gag-specific CTL responses in the context of H-2d, but
s
dnot H-2b (Schwarz and Green, 1994; Mayrand et al., 1998;
Mayrand and Green, 1998). Taken together, our studies
suggest that a primary factor in the determination of
MAIDS resistance versus susceptibility most likely is the
codominant expression of the resistant H-2d haplotype,
hich allows for Kd-restricted CD81 CTL production. In-
deed, our experiments, in which chronic in vivo depletion
of CD81 T cells in genetically resistant mice caused
hem to become MAIDS susceptible (Fig. 1), provide
irect linkage of the ability to raise anti-gag CTLs with
esistance. These findings are in agreement with the
esults of Makino et al. (1992), which demonstrated that
esistant A/J mice were rendered susceptible to MAIDS
fter in vivo depletion of the CD81 T-cell population.
Interestingly, however, 19% of H-2d/b and 23% of the re-
sistant H-2d/d F2 mice had at least one clinical aspect of
MAIDS, suggesting that a non-MHC genetic determinant
can negatively influence T-cell protection and thus dis-
ease outcome.
MATERIALS AND METHODS
Mice
BALB/cByJ (H-2d), C57BL/KsJ (H-2d), C57BL/6J (H-2b),
and CBY6F1 (H-2
d3b) mice (4 weeks old) were obtained
from The Jackson Laboratories (Bar Harbor, ME). Addi-
tional CBY6F1 (H-2
d3b) mice were produced by breeding
ALB/cByJ and C57BL/6J mice at the animal facility of
he Scripps Research Institute. CBY6F2 H-2
b/b, H-2d/d, and
-2d/b mice were generated by inter-cross-breeding of
the CBY6F1 (H-2
d3b) mice at the animal facility of The
Scripps Research Institute. At 4 weeks of age, mice were
MHC typed by a PCR-based assay (see later).
CD81 T-cell depletion in vivo
To test the effect of depletion of CD81 T cells in a
AIDS-resistant mouse strain, prototypic MAIDS-resis-
ant, adult BALB/cByJ mice were injected i.p. with 0.25 ml
;0.25 mg) purified ascites fluid containing the murine
CD8-specific mAb 53-6.72 (IgG2a rat anti-mouse, TIB 105;
merican Type Culture Collection, Rockville, MD.) on day
after LP-BM5 virus infection. Identical weekly injections
f anti-CD8-containing ascites were delivered i.p. (up to
weeks before sacrifice) to maintain depletion through-
ut the course of the experiment. Flow cytometric anal-
sis was performed periodically on splenocytes derived
rom control mice that received the same regimen of
nti-CD8 mAb to confirm efficient chronic depletion of
D81 T cells (i.e., .95% reduction in percent CD81
cells).
Medium
In addition to L-glutamine (2 mM), penicillin (30 mg/ml),
treptomycin (20 mg/ml), and gentamicin (33 mg/ml), me-
ium contained the following additional components:
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447ANTI-GAG CTLs SPECIFIC FOR AN ALTERNATIVE ORFRPMI-10 (RPMI 1640 and 10% FBS), RPMI-10ME
(RPMI-10 plus 50 mM 2-mercaptoethanol), DMEM-10
(Dulbecco’s modified Eagle’s medium, 10 mM HEPES,
and 10% FBS), sensitization media (SM: RPMI-10ME plus
0.1 M nonessential amino acids, 1 mM sodium pyruvate),
and SM-rIL2 (SM plus 8 units/ml recombinant interleu-
kin-2). RPMI 1640 containing 10% calf serum was used
for conducting 51Cr release assays.
Cell lines
The murine lines J774.2 (macrophage, H-2d; American
Type Culture Collection) passaged in DMEM-10, P815B
(mastocytoma, H-2d, a generous gift from Dr. Jack Ben-
nink, National Institutes of Health, National Institute of
Allergy and Infectious Diseases, Bethesda, MD) pas-
saged in RPMI-10ME, and Yac-1 (Moloney murine leuke-
mia virus-induced tumor, H-2a) passaged in RPMI-10
ere used in this series of experiments.
P-BM5 virus
LP-BM5 virus was prepared in our laboratory as de-
cribed by Klinken et al. (1988). G6 cells, originally pro-
ided to us by Drs. Jane Hartley and Herbert Morse as a
loned cell line from SC-1 cells infected with the LP-BM5
irus mixture, were cocultured with noninfected SC-1
ells and cell-free supernatants were harvested, Milli-
ore filtered, and titered. Mice were infected intraperito-
eally with 0.25 ml of virus stock that was quantified by
n XC plaque assay (Rowe et al., 1970) to contain ap-
roximately 7 3 105 ecotropic plaque-forming units
(pfu)/ml.
Recombinant viruses
Kd-Vac, a recombinant vaccinia virus encoding the
H-2Kd class I molecule, was a generous gift from Dr. Jack
ennink. Additional recombinant vaccinia and Sindbis
iruses were generated using established protocols
Earl and Moss, 1993; Hahn et al., 1992). Intermediate
huttle vectors, used to create the indicated recombinant
iruses described later, were constructed using estab-
ished procedures (Sambrook et al., 1989) or manufac-
urer-specified protocols. The pSC65 shuttle vector and
he Western Reserve isolate of vaccinia virus were gen-
rously provided by Dr. Bernard Moss (National Insti-
utes of Health, National Institute of Allergy and Infec-
ious Diseases, Bethesda, MD). The vectors for recom-
inant Sindbis virus generation, pH392J1 (shuttle vector)
nd pTE392J:CAT, were generously provided by Dr.
hang Hahn (University of Virginia, Charlottesville, VA).
lasmid maps will be provided on request. The construc-
ion of the recombinant vaccinia and Sindbis viruses
xpressing ecotropic gag (eG), defective gag (dG), or
ortions of dG have previously been published (Schwarz
nd Green, 1994; Mayrand et al., 1998). Briefly, for vac-
inia, inserts were cloned into the shuttle vector pSC65,nd the following recombinant viruses were generated
ia homologous recombination between pSC65 and the
estern Reserve isolate of vaccinia virus: dG-Vac, con-
aining the entire def-gag sequence (AA 1–532 of the
1/27/A1 retrovirus clone), and eG-Vac, containing the
ntire ecotropic gag sequence (AA 1–536 of the pEco12
etrovirus clone), which were the generous gifts of Dr.
isir Chattopadhyay, National Institutes of Health, Na-
ional Institute of Allergy and Infectious Diseases, Be-
hesda, MD (Chattopadhyay et al., 1991). The construc-
ion of recombinant Sindbis viruses has also been de-
cribed in detail (Schwarz and Green, 1994; Mayrand et
l., 1998). Briefly, inserts were cloned into the shuttle
ector pH392J1, a fragment containing the insert and
ubgenomic promoter was subcloned into the full-length
indbis cDNA contained in pTE392J:CAT, and infectious
indbis virus was recovered after LipoFECTIN (GIBCO
RL, Grand Island, NY)-mediated transfection of viral
NA into BHK-21 (cl.13) cells to create the recombinant
iruses encoding the following portions of dG AA 1–532:
IN:dG (1–342), SIN:dG (208–240), and SIN:dG (208–225).
nfection of stimulator and target cells
Next 1 3 107 (vaccinia virus) or 5 3 107 (Sindbis virus)
pfu was added to 1 3 106 P815B or J774.2 cells in 500 ml
f a balanced salt solution containing 0.1% BSA and
llowed to adsorb for 1 h at 37°C with agitation. For
accinia target cells, samples were incubated at 37°C for
n additional 3 h. before 51Cr labeling. Sindbis targets
ere infected in the same manner but were allowed to
xpress viral proteins for a minimum of 6 h before 51Cr
abeling. Under these infection conditions, including this
0:1 m.o.i. for Sindbis virus, essentially 100% of target
nd stimulator cells infected by the recombinant viruses
ave previously been shown by flow cytometry and other
echniques to express the inserted retroviral protein se-
uence (Schwarz and Green, 1994; unpublished obser-
ations).
ynthetic peptides
The ORF2 peptide (SYNTGRFPPL) was synthesized
ith unmodified NH2- and COOH-terminal amino acids
using fluorenylmethoxycarbonyl (FMOC)-based chemis-
try by Research Genetics (Huntsville, AL).
Generation of bulk cytolytic effector cells
Six to 10-week-old mice were infected intravenously
with 1–2 3 107 pfu dG-Vac, 2 3 107 pfu eG-Vac, or 1.8 3
105 pfu LP-BM5 virus. At least 3 weeks postinfection for
ecombinant vaccinia priming or 7–10 days for LP-BM5
riming, primed mice were sacrificed and splenic leuko-
ytes were recovered. As a source of stimulatory anti-
en, 1 3 106 P815B or J774.2 cells were irradiated (8000rads), infected with the appropriate recombinant virus,
and added to 4 3 107 to 5 3 107 primed leukocytes in
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448 MAYRAND ET AL.MLTC cocultures. Vaccinia virus-specific effectors were
generated by directly adding vaccinia virus (dG-Vac or
Kd-Vac) to responder cells at an m.o.i. of 10:1. Peptide
stimulation was achieved by the addition at a final con-
centration of 10 mg/ml. Our previous studies have shown
hat even for recombinant vaccinia virus-mediated in vivo
riming of resistant mice, both in vivo priming and in vitro
estimulation with sources of retroviral epitopes are nec-
ssary for easy detection of antiviral CTL activity in both
he MAIDS and other murine retroviral systems (Schwarz
nd Green, 1994; unpublished observations). Cells were
ultured in MLTC in RPMI-10 for 6 days at 37°C in a
umidified 5% CO2 atmosphere.
Chromium release assay
Target cells (106 to 2 3 106) were resuspended in 100
ml of FBS and labeled with 200 mCi of 51Cr sodium
chromate (New England Nuclear, Wilmington, DE) for 45
min at 37°C. After washing, 4 3 103 or 104 target cells
ere combined with serial dilutions of effector cells in
6-well V-bottom plates. After a 4-h incubation at 37°C,
00 ml of cell-free supernatant was collected and
ounted. Percent specific lysis of tumor cells was deter-
ined using the formula [(a 2 b)/c] 3 100, where a is
experimental counts per minute released by target cells
incubated with effector cells, b is counts per minute
released by target cells incubated alone (spontaneous
release), and c is counts per minute released by the
freeze-thaw of target cells (approximately 80% of total
counts per minute incorporated), and ,10% variation
was seen between experimental replicates.
RT–PCR
Total RNA was recovered from target cells using a
CsTFA-based kit from Pharmacia (Piscataway, NJ) and
standard procedures previously described (Schwarz and
Green, 1994; Mayrand et al., 1998). After ethanol precip-
itation, each cDNA sample was subjected to 30 cycles of
Taq polymerase amplification consisting of 45 s denatur-
ation at 94°C, 60 s annealing at 50°C, and 90 s chain
elongation at 72°C with the following primers: pH39-59,
59-GGAAATAAAGCATCTCTACG-39, and pH39165, 59-
CTAATGTACCAGCCTGATGC-39.
MHC genotyping
F2 mice produced by CBY6F1 (H-2
d3b) inter-cross-
breeding were typed for their MHC by microsatellite
analysis (Dietrich et al., 1992) using a rapid DNA screen-
ing protocol developed by Chen and Evans (1993). Tis-
sue was obtained from the ear or the last 0.5 mm of the
tail of 4- to 5-week-old mice and digested using Protein-
ase K digestion, and the DNA was prepared for PCR
amplification as described by Chen and Evans (1993).
The DNA samples were amplified with primers to
D17Mit28 (MAPPAIRS, Research Genetics, Inc., Hunts-ville, AL), which allows the MHC haplotype determination
of mice as H-2d, H-2b, and H-2d3b through the detection of
nown microsatellites (see Dietrich et al., 1992 and http://
ww.informatics.jax.org/searches/marker_form.shtml).
CRs were in 25-ml volumes using standard reagents
(Perkin–Elmer Cetus, Norwalk, CT) with concentrations
of 1.5 mM MgCl2 and primers to 0.4 M. Reactions were
carried out for 35 cycles at 94°C for 30 s, 55°C for 30 s,
and 72°C for 1 min. All PCR analyses included reagent
only reactions to control for false-positives. The PCR
products, 10 ml, were run out on 6% acrylamide gels, and
he bands were visualized with ethidium bromide stain-
ng. PCR product from the amplification of DNA from the
solated from the tissues of H-2d, H-2b, and H-2d3b mice
were run on each gel to serve as a positive size control
for distinguishing bands from the PCR product of DNA
obtained from the mice to be typed.
Detection of defective gag viral genomes
F2 mice injected with LP-BM5 virus were evaluated
for MAIDS by both clinical (as above) and molecular
means. To determine the presence of integrated de-
fective virus. DNA samples were obtained from the
spleen and lymph nodes of mice (as described earlier)
and assessed for the presence of the p12 region of
defective virus by PCR analysis. Primers to the defec-
tive p12 region were as described (Ogata et al., 1993).
All samples included DNA from noninfected mice and
mice infected with pEco12, a cloned ecotropic murine
leukemia virus (kindly provided by Dr. S. Chatto-
padhyay, Laboratory of Immunopathology, National In-
stitute of Allergy and Infectious Diseases), and known
MAIDS positive mice as controls. PCRs were in 25-ml
olumes using standard reagents (Perkin–Elmer Ce-
us) with concentrations of 1.5 mM MgCl2 and primers
to 0.5 M. Reactions were carried out for 35 cycles at
94°C for 30 s, 60°C for 30 s, and 72°C for 1 min. PCR
products were detected as described above.
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